NEW YORK and LONDON, August 10, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, …
Press Release
Akari Therapeutics to Present Data from Phase 2 PNH Trial of Coversin at the 22nd Congress of the European Hematology Association
NEW YORK and LONDON, June 23, 2017 -- Akari Therapeutics (NASDAQ: AKTX), a clinical-stage biopharmaceutical company, is presenting a poster today at the 22nd …
Akari Therapeutics Announces Resignation of CEO
- Executive Chairman to Continue to Fulfill Interim CEO Duties as Board Commences Executive Search - Data Correction for Fifth Patient in Phase 2 PNH Trial for …
[Read more...] about Akari Therapeutics Announces Resignation of CEO
Akari Therapeutics Announces Edison’s Withdrawal of Edison Report titled “Akari’s Coversin matches Soliris in Phase II”
NEW YORK and LONDON, April 27, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, released today a …
Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and In Additional Clinical Targets
NEW YORK and LONDON, April 24, 2017 -Interim Phase 2 PNH data demonstrate positive response with Coversin™ -Phase 3 PNH program expected to commence in …
